MONICA PIQUERAS

Dr. MONICA PIQUERAS

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
RMRaúl Méndez
Raúl Méndez
ALAna Latorre
Ana Latorre
MPMONICA PIQUERAS
MONICA PIQUERAS
MBMaría Nieves Balaguer-Cartagena
María Nieves Balaguer-Cartagena
RMRosario Menéndez
Rosario Menéndez
The role of NETs and platelet activation in COVID-19 is scarcely known. We aimed to evaluate the role of NETs (citrullinated histone H3 [CitH3], cell-free DNA [cfDNA]) and platelet activation markers (soluble CD40 ligand [CD40L] and P-selectin) in estimating the hazard of different clinical trajectories in patients with COVID-19. We performed a prospective study of 204 patients, categorized as outpatient, hospitalized and ICU-admitted. A multistate model was designed to estimate probabilities of clinical transitions across varying states, such as emergency department (ED) visit, discharge (outpatient), ward admission, ICU admission and death. Levels of cfDNA, CitH3 and P-selectin were associated with the severity of presentation and analytical parameters. The model showed an increased risk of higher levels of CitH3 and P-selectin for ED-to-ICU transitions (Hazard Ratio [HR]: 1.35 and 1.31, respectively), as well as an elevated risk of higher levels of P-selectin for ward-to-death transitions (HR: 1.09). Elevated levels of CitH3 (HR: 0.90), cfDNA (HR: 0.84) and P-selectin (HR: 0.91) decreased the probability of ward-to-discharge transitions. A similar trend existed for elevated levels of P-selectin and ICU-to-ward transitions (HR 0.40); In conclusion, increased NET and P-selectin levels are associated with more severe episodes and can prove useful in estimating different clinical trajectories.

Verified
Journal Article
Open access
PDF file
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
RMRaúl Méndez
Raúl Méndez
ALAna Latorre
Ana Latorre
NMNoé Mengot
Noé Mengot
MPMONICA PIQUERAS
MONICA PIQUERAS
RMRosario Menéndez
Rosario Menéndez
COVID-19 has been a diagnostic and therapeutic challenge. It has marked a paradigm shift when considering other types of pneumonia etiology. We analyzed the biomarkers related to endothelial damage and immunothrombosis in COVID-19 in comparison to community-acquired pneumonia (CAP) through a case–control study of 358 patients with pneumonia (179 hospitalized with COVID-19 vs. 179 matched hospitalized with CAP). Endothelial damage markers (endothelin and proadrenomedullin), neutrophil extracellular traps (NETs) (citrullinated-3 histone, cell-free DNA), and platelet activation (soluble P-selectin) were measured. In-hospital and 1-year follow-up outcomes were evaluated. Endothelial damage, platelet activation, and NET biomarkers are significantly higher in CAP compared to COVID-19. In-hospital mortality in COVID-19 was higher compared to CAP whereas 1-year mortality and cardiovascular complications were higher in CAP. In the univariate analysis (OR 95% CIs), proADM and endothelin were associated with in-hospital mortality (proADM: CAP 3.210 [1.698–6.070], COVID-19 8.977 [3.413–23.609]; endothelin: CAP 1.014 [1.006–1.022], COVID-19 1.024 [1.014–1.034]), in-hospital CVE (proADM: CAP 1.623 [1.080–2.439], COVID-19 2.146 [1.186–3.882]; endothelin: CAP 1.005 [1.000–1.010], COVID-19 1.010 [1.003–1.018]), and 1-year mortality (proADM: CAP 2.590 [1.644–4.080], COVID-19 13.562 [4.872–37.751]; endothelin: CAP 1.008 [1.003–1.013], COVID-19 1.026 [1.016–1.037]). In conclusion, COVID-19 and CAP showed different expressions of endothelial damage and NETs. ProADM and endothelin are associated with short- and long-term mortality.

21 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
MPMONICA PIQUERAS
MONICA PIQUERAS
ACANA LATORRE CAMPOS
ANA LATORRE CAMPOS
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
NMNoé Mengot
Noé Mengot
RMRaúl Méndez
Raúl Méndez
Background: Complications in community-acquired pneumonia (CAP), including cardiovascular events (CVE), can occur during an acute episode and in the long term. We aimed to analyse the role of endothelial damage biomarkers (C-terminal endothelin-1 precursor fragment [CT-proET-1] and mid-regional pro-adrenomedullin [MR-proADM]), in contrast to classic inflammation markers (C Reactive Protein [CRP] and procalcitonin [PCT]) in patients admitted for CAP and their relationship with ICU admission, CVE and mortality in the short and long term; Methods: Biomarkers were analysed in 515 patients with CAP at day 1, 285 at day 5 and 280 at day 30. Traditional inflammatory biomarkers and endothelial damage biomarkers were measured. ICU admission, CVE and mortality (in-hospital and 1-year follow-up) were assessed using receiver operating characteristic (ROC) curve analysis and univariate logistic regression. Results: A statistically significant association was observed between initial, raised CT-proET-1 and MR-proADM levels, the need for ICU admission and the development of in-hospital CVE or in-hospital mortality. Both endothelial markers maintained a strong association at day 30 with 1-year follow-up CVE. At day 1, CRP and PCT were only associated with ICU admission. On day 30, there was no association between inflammatory markers and long-term CVE or death. The odds ratio (OR) and area under the curve (AUC) of endothelial biomarkers were superior to those of classic biomarkers for all outcomes considered. Conclusions: Endothelial biomarkers are better indicators than classic ones in predicting worse outcomes in both the short and long term, especially CVE. MR-proADM is the best biomarker for predicting complications in CAP.

6 March 2026 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
MPMONICA PIQUERAS
MONICA PIQUERAS
CCCarlos Cátedra
Carlos Cátedra
AVAna Vañó-Bellver
Ana Vañó-Bellver
DDDiana Domingo-Valero
Diana Domingo-Valero
BLBegoña Laiz-Marro
Begoña Laiz-Marro

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
RMRaúl Méndez
Raúl Méndez
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
ALAna Latorre-Pellicer
Ana Latorre-Pellicer
MPMONICA PIQUERAS
MONICA PIQUERAS
LBLeyre Bouzas
Leyre Bouzas
RMRosario Menéndez
Rosario Menéndez
Introduction: Endothelial injury is related with poor outcomes in respiratory infections but insufficient is known in COVID-19. The aim of the study was to analyse endothelial damage in COVID-19 during the acute phase and in the follow-up. Methods: Longitudinal study in COVID-19 patients, confirmed by reverse transcription polymerase chain reaction. Patients with initial ward admission, initial intensive care unit (ICU) admission and outpatients were included. Endothelial damage was evaluated with plasma proadrenomedullin (proADM) and proendothelin. Biomarkers were obtained at the emergency department (ED) visit (T1) and in the follow-up visit (T2) after discharge, and compared with controls. Results: 210 patients (23 outpatients, 179 initial ward admitted and 8 initial ICU admitted) were included for the analysis of biomarkers on day 1 and, in 97 patients, data were obtained in both day 1 and follow-up visit. ProADM and proendothelin levels at T1 and T2 were higher compared to controls. Initial higher proADM and/or proendothelin levels were associated with most severe episodes, ICU admitted compared to ward admitted and outpatients. High levels at T1 of proADM or proendothelin were associated with in-hospital mortality by Kaplan-Meier analysis (log-rank test). ProADM and proendothelin concentration at T2 presented a positive correlation with C-reactive protein, cardiac damage, and D-dimer concentration. Patients with residual endothelial damage more frequently presented altered DLCO and lack of radiological resolution compared to those without residual damage. Conclusion: Acute and sustained endothelial damage is associated with poor prognosis and respiratory sequelae respectively.

31 January 2026 in Archivos de Bronconeumología
Verified
Journal Article
Open access
PGPaula González-Jiménez
Paula González-Jiménez
MPMONICA PIQUERAS
MONICA PIQUERAS
ALAna Latorre
Ana Latorre
NMNoé Mengot
Noé Mengot
LMLeila Mokachir
Leila Mokachir
RMRaúl Méndez
Raúl Méndez